See also this year's filing and all EDGAR filings for this company.
PDF Report 0001349929_2014_Vyant_Bio_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | No stock price available | subcommand.plot | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.18769929916430603, 'aggregate_val': 47105130, 'exp_sum': 57989769, 'exp_to_value': {'IntangibleAssets': 2994135, 'AssetsNonCurrent': 10884639, 'AssetsCurrent': 31773898, 'PropertyPlantAndEquipment': 4446593, 'remainder_Assets': 7890504}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001349929')"} |
Graph
Absolute values for 0001349929, Vyant Bio Inc
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 2,001,430 |
| 2 | AssetsCurrent | 51,891,219 |
| 3 | PropertyPlantAndEquipment | 1,264,624 |
| 4 | remainder_Assets | 0 |
| 5 | LongTermLiabilities | 0 |
| 6 | LiabilitiesCurrent | 8,619,498 |
| 7 | remainder_Liabilities | 1,074,566 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 4,924,626 |
| 10 | GeneralAndAdministrativeExpense | 6,115,035 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 1,841,675 |
| 15 | ResearchAndDevelopmentExpense | 2,190,204 |
| 16 | remainder_Expenses | -663,900 |
| 17 | remainder_Revenues | 6,609,957 |
| 18 | remainder_NetIncome | -4,574,870 |
| 19 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 55,157,273 |
| 1 | Liabilities | 9,694,064 |
| 2 | Expenses | 14,407,640 |
| 3 | Revenues | 6,609,957 |
| 4 | StockholdersEquity | 45,463,209 |
| 5 | NetIncome | -12,372,553 |
| 6 | ComprehensiveNetIncome | -12,372,553 |
| 7 | BaseVar | 45,221,902 |
| 8 | EconomicCapitalRatio | 3.52 |
Edgar->Model Mapping
Feature Distribution
